We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » MULTIPLE GENERIC FIRMS HOLDING BACK ON LUCRATIVE PAROXETINE MARKET
MULTIPLE GENERIC FIRMS HOLDING BACK ON LUCRATIVE PAROXETINE MARKET
March 23, 2004
More than two weeks after receiving FDA final approval, generic firms Sandoz and Alphapharm have yet to market their versions of GlaxoSmithKline’s (GSK’s) profitable antidepressant Paxil (paroxetine HCl).